A 25-year-old Caucasian female with multiple genital warts involving the vulvar area was treated with imiquimod 5% cream. During follow-up the patient developed areas of hypopigmentation at the site of application of imiquimod cream and areas of hypomelanosis around multiple preexisting nevi of the trunk. At 18 months follow-up genital depigmentation persisted and halo nevi of the trunk were still present. Different mechanisms of imiquimod-induced depigmentation have been reported. Halo nevi are considered expression of an autoimmune response. In the case presented here, it might be conceivable that both vitiligo-like depigmentation at the site of application and halo of hypomelanosis around melanocytic nevi have been induced by the same immunologic mechanism elicited by topical application of imiquimod.
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INTRODUCTION
Imiquimod 5% cream is currently approved for topical treatment of genital warts, superficial basal cell carcinoma and actinic keratoses. So far, several cases of vitiligo-like imiquimod-induced depigmentation have been reported.
1,2 The present case report refers to the observation of vulvar depigmentation and onset of multiple halos of hypomelanosis around several melanocytic nevi of the trunk following treatment with imiquimod 5% cream for vulvar condylomata (Figures 1 and 2 ).
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CASE REPORT
A 25-year-old Caucasian female with genital warts was treated with imiquimod 5% cream three times weekly for 12 weeks .The treatment was well tolerated .At 4-month follow-up after discontinuation, the patient was noted to have some residual condylomata and marked depigmentation at the site of application.
At 8-month follow-up she was noted do have developed halos of hypomelanosis around four pre- 
DISCUSSION
The case presented here was characterized by the co-existence of genital vitiligo-like depigmentation and appearance of several halo nevi of the trunk. (Figures 3 and 4) . 3, 4, 5 Different mechanisms of imiquimod-induced depigmentation have been reported including postinflammatory depigmentation, necrosis of melanocytes and immune mediated vitiligo-like reactions. 6, 7 As vitiligo may be expression of a cytotoxic T lymphocyte immune reaction, it may be conceivable that imiquimod could contribute to the elimination of melanocytes by inducing acquired immunity through the induction of cytokines. 1, 6, 7 If this is true, it is likely that both vitiligo-like depigmentation at the site of application and halo of hypomelanosis around melanocytic nevi of the trunk have been induced by the same immunologic mechanism evoked by topical application of imiquimod.
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